News : Press Note

Salius Pharma Reveals Ambitious Three-Year Expansion Strategy for Central Asia & CIS Market

Mumbai, August 11, 2025 —

Salius Pharma, a rapidly growing Indian pharmaceutical company, has unveiled an extensive three-year strategic plan to further expand its footprint in Central Asia and CIS countries. Under the visionary leadership of Mr. A.K. Patra, Managing Director, the company aims to strengthen healthcare availability by providing high-quality APIs, affordable generics, and specialty drugs tailored to meet the evolving medical needs of the region.

.

Strategic Objectives for 2025–2028

1. Broader Market Coverage

Salius Pharma will target Kazakhstan, Uzbekistan, Kyrgyzstan, Tajikistan, Turkmenistan, Azerbaijan, Armenia, Georgia, Belarus, and Russia, with plans for registrations and launches of key molecules addressing local health priorities.

2. Focus on High-Priority Therapeutic Segments

The company will prioritize APIs in dermatology, anti-infectives, antiparasitic, and chronic care categories, with molecules such as Selenium Sulfide, Metronidazole, Albendazole, Ivermectin, and Ketoconazole leading the portfolio.

3. Regulatory & GMP Compliance

Product registrations will be accelerated in line with Eurasian Economic Union (EAEU) and country-specific regulatory frameworks to ensure faster market access and sustainable presence.

4. Local Manufacturer Partnerships

By collaborating with regional formulators, distributors, and government health authorities, Salius Pharma intends to boost local manufacturing capacity and establish resilient supply chains.

5. R&D and Custom Formulations

The company plans to introduce tailor-made products designed to meet the climatic, demographic, and epidemiological needs specific to Central Asia and the CIS markets.

Sharing the announcement, Mr. A.K. Patra, Managing Director of Salius Pharma, stated:

“Central Asia and the CIS region present a significant challenge in bridging healthcare disparities. Over the next three years, we will focus on building strong, long-term partnerships and delivering products that meet both quality and affordability standards. Our objective is to be a trusted healthcare partner in every market we serve.”

Commitment to the Region

Salius Pharma’s growth strategy aligns with its global mission to provide affordable, quality healthcare solutions to emerging and underserved markets. With a comprehensive product portfolio, proven regulatory expertise, and reliable supply chain capabilities, the company is well-positioned to make a meaningful impact on public health across Central Asia and the CIS.

Media Contact:

Salius Pharma Communications Team
 Email: info@saliuspharma.com

 Website: https://saliuspharma.com